Altering Protein Functional Properties Through Terminal Fusions

ABSTRACT

The invention provides isolated terminal fusion glycinin and proglycinin polypeptides that when expressed alter the functional properties of the protein in comparison with wild type. Also provided are nucleic acid sequences that encode the terminal fusion polypeptides, and methods of modifying the functional properties of glycinin proteins.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of co-pending application U.S.application Ser. No. 10/795,062 filed Mar. 5, 2004 which claims priorityto and the benefit of U.S. Provisional Application No. 60/453,132 filedMar. 7, 2003, all of which are herein incorporated by reference.

BACKGROUND OF THE INVENTION

Glycinin is a major soybean seed storage protein used extensively in soyfood products. However, these proteins have functional properties thatdo not make them ideally suited in all product applications.

It has been found that the functional properties (emulsification,gelation, solubility, etc.) of a protein are directly related to aminoacid composition, sequence, and structure. Therefore, the properties canbe altered through protein engineering.

Currently, improvement in soy protein functionality has been achievedthrough protein engineering of the core amino acid sequence. However,these alterations are limited due to the necessity of maintaining thewild-type three-dimensional structure so that the protein can assemblecorrectly.

The present invention provides methods and compositions for changing theproperties of glycinin without having to alter the core structureresponsible for correct assembly. This approach provides greaterflexibility, allowing more radical changes than might be tolerated byalterations to the native protein structure.

DETAILED DESCRIPTION OF THE INVENTION

Glycinin is an 11S soybean globulin composed of six subunits. Eachsubunit is synthesized as a single polypeptide precursor containing anacidic region, a basic region, and an endoplasmic reticulum (ER) signalpeptide. This precursor is preproglycinin. The signal peptide is removedby a first cleavage in the endoplasmic reticulum and the subunitsassemble into trimers to form proglycinin. Preferably, modifications tothe protein sequence should not disrupt this formation of trimers,because monomers are proteolytically unstable and unlikely to accumulateto useful levels. The proglycinin trimers move into protein storagevacuoles where a post-translational (second) cleavage by the vacuolarprocessing enzyme (VPE) results in hexamers that are glycinin. Thissecond cleavage, between an asparagine and glycine residue at thejunction of the acidic and basic regions, is highly conserved andconsidered a diagnostic characteristic of 11S globulins (see, forexample, PubMed accession number M36686); (Dickinson et al., Plant Cell1:459-469 (1989); Jung et al., Plant Cell 10:343-357 (1998). Improvedfunctional properties of either proglycinin trimers or glycinin hexamersare potentially useful. It is thought that evaluation of the assemblyand functional properties of E. coli-expressed proglycinin mutants ishelpful in predicting properties of the corresponding glycinin mutants(Kim et al., Agric. Biol. Chem. 54:1543-1550 (1990); Kim et al., ProteinEng. 3:725-731 (1990)).

Glycinin polypeptides are encoded primarily by 5 genes: Gy1, Gy2, Gy3,Gy4, and Gy5, (Nielsen et al., Plant Cell 1:313-328 (1989)), and to alesser extent by at least one other gene, Gy7 (Beilinson et al., Theor.Appl. Genet. 104:1132-1140 (2002)). In soybeans, glycinin hexamers arecomprised of a heterogeneous mixture of the different glycinin geneproducts in various ratios. Changes in properties of any of thepolypeptides encoded by any of the glycinin genes are potentially usefulin improving functional properties.

Proglycinin1 and proglycinin4 (products of the Gy1 and Gy4 genes) werepreviously modified at non-conserved regions of the sequence to try toimprove nutritional value or functional properties (Kim et al., ProteinEng. 3:725-731 (1990); Dickinson et al., Plant Cell 2:403-413 (1990)).Some, but not all of the mutant polypeptides assembled into trimers.Deletion of proglycinin disulfide bonds was also examined to assesseffects on functional properties (Utsumi et al., J. Agric. Food Chem.41:687-691 (1993). However, fusion of polypeptides to proglycinin orglycinin for the purpose of improving functional properties has not beenpreviously explored.

The reporter protein chloramphenicol acetyl transferase was fused to theC-terminus of legumin, a glycinin homolog from Vicia faba, in order tostudy assembly and processing of 11S globulins. The fusion protein didnot accumulate in plants, however, suggesting that the approach offusing proteins to 11S globulins would be difficult. (Jung et al., J. ofExp. Botany 44:343-349).

It has been unexpectedly found that terminal fusions facilitate a changein the properties of the protein without having to alter the glycinin orproglycinin core sequence. Further, it is feasible to alter proteinfunctional properties by the selection of fusion partners that possessthe desired characteristics.

The fusion proteins of the present invention are produced by creatingDNA constructs operably linking nucleic acid sequences encodingpolypeptides having desired characteristics (e.g., acidic, basic,hydrophobic, hydrophilic), to a nucleic acid sequence encoding a soybeanproglycinin polypeptide at either the C or N terminus, or both. Theconstruct can include a linker sequence between proglycinin and thepolypeptide being fused to it. The construct is then inserted into anexpression cassette for transformation into plants or into bacterialexpression systems. The fusion proteins can be produced in the hexamericglycinin form through expression in plants, or through expression in E.coli and subsequently adding VPE to the purified protein. Alternatively,the fusion proteins could be made in the trimeric, proglycinin(unprocessed), form through expression in E. coli and not adding VPE tothe purified protein, or through expression in plants that are deficientin VPE activity (Gruis et al., Plant Cell 14:2863-2882, (2002); Gruis etal., Plant Cell 16:270-290 (2004)), or through expression in plants in asubcellular location different from the VPE location (Kinney et al.,Plant Cell 13:1165-1178, (2001).

Units, prefixes, and symbols can be denoted in their Si accepted form.Unless otherwise indicated, nucleic acids are written left to right in5′ to 3′ orientation; amino acid sequences are written left to right inamino to carboxy orientation, respectively. Numeric ranges are inclusiveof the numbers defining the range and include each integer within thedefined range. Amino acids can be referred to herein by either theircommonly known three letter symbols or by the one-letter symbolsrecommended by the IUPAC-IUB Biochemical Nomenclature Commission.Nucleotides, likewise, can be referred to by their commonly acceptedsingle-letter codes. The terms defined below are more fully defined byreference to the specification as a whole.

modified: measurably different from wild-type

functional properties: include but not limited to: solubility, waterabsorption and binding, viscosity, gelation (including gel firmness,translucence, and gelation temperature), cohesion-adhesion, elasticity,emulsification, fat adsorption, flavor-binding, foaming and colorcontrol. See Kinsella, J.E., J. Am. Oil Chem. Soc. 56:242-258 (1979).

expression cassette: a set of control sequences including initiation,promoter, and termination sequences which function in a plant cell whenthey flank a structural gene in the proper reading frame. Expressioncassettes frequently and preferably contain an assortment of restrictionsites suitable for cleavage and insertion of any desired structuralgene.

solubility: dispensability in fluid as measured by the nitrogensolubility index (NSI) or protein dispersibility index (PDI). SeeJohnson, D. W., Food Prod. Dev. 3:78 (1970); and J. Am. Oil Chem. Soc.47:402 (1970), herein incorporated by reference. The solubility of aprotein solution can be measured by incubation for the desired time inthe desired conditions, centrifuging at 17,000 g for 10 minutes, andassaying the supernatant for protein content.

gel-forming or gelation: the ability of protein to form athree-dimensional matrix of intertwined, partially associatedpolypeptides in which water can be held. See Kinsella, J. E., J. Am. OilChem. Soc. 56:242-258 (1979); herein incorporated by reference.

emulsifying or emulsification: the ability of protein to aid the uniformformation and stabilization of fat emulsions. See Kinsella, J. E., J.Am. Oil Chem. Soc. 56:242-258, (1979); herein incorporated by reference.

operably linked: A first nucleic acid sequence is operably linked with asecond nucleic acid sequence when the first nucleic acid sequences isplaced in a functional relationship with the second nucleic acidsequence. For example, a promoter is operably linked to a codingsequence if the promoter affects the transcription or expression of thecoding sequence. Generally, operably linked DNA sequences are contiguousand, where necessary, join two protein-coding regions in the samereading frame. With respect to polypeptides, two polypeptide sequencescan be operably linked by covalent linkage, such as through peptidebonds or disulfide bonds. Additionally, nucleic acid and polypeptidesequences can be operably linked through a linker sequence. Such linkersequences provide flexibility and spacing, or facilitates constructionof expression cassettes, while maintaining desired function.

soybean protein product: a soy flour, a concentrate, or an isolate andproducts made with soy flours, concentrates, or isolates. (Kinsella, J.E., J. Am. Oil Chem. Soc. 56:242-258 (1979).

By “encoding” or “encoded”, with respect to a specified nucleic acid, ismeant comprising the information for translation into the specifiedprotein. A nucleic acid encoding a protein can comprise non-translatedsequences (e.g., introns) within translated regions of the nucleic acid,or can lack such intervening non-translated sequences (e.g., as incDNA). The information by which a protein is encoded is specified by theuse of codons. Typically, the amino acid sequence is encoded by thenucleic acid using the “universal” genetic code. However, variants ofthe universal code, such as are present in some plant, animal, andfungal mitochondria, the bacterium Mycoplasma capricolum, or the ciliateMacronucleus, can be used when the nucleic acid is expressed therein.

By “non-human host cell” is meant a cell which contains a vector andsupports the replication and/or expression of the vector. Host cells canbe prokaryotic cells such as E. Coli, or eukaryotic cells such as yeast,insect, amphibian, or mammalian cells excluding humans. Preferably, hostcells are monocotyledonous or dicotyledonous plant cells.

The term “introduced” in the context of inserting a nucleic acid into acell, means “transfection” or “transformation” or “transduction” andincludes reference to the incorporation of a nucleic acid into aeukaryotic or prokaryotic cell where the nucleic acid can beincorporated into the genome of the cell (e.g., chromosome, plasmid,plastid or mitochondrial DNA), converted into an autonomous replicon, ortransiently expressed (e.g., transfected mRNA).

The terms “isolated” refers to material, such as a nucleic acid or aprotein, which is: (1) substantially or essentially free from componentsthat normally accompany or interact with it as found in its naturallyoccurring environment. The isolated material optionally comprisesmaterial not found with the material in its natural environment; or (2)if the material is in its natural environment, the material has beensynthetically (non-naturally) altered by deliberate human interventionto a composition and/or placed at a location in the cell (e.g., genomeor subcellular organelle) not native to a material found in thatenvironment. The alteration to yield the synthetic material can beperformed on the material within or removed from its natural state. Forexample, a naturally occurring nucleic acid becomes an isolated nucleicacid if it is altered, or if it is transcribed from DNA which has beenaltered, by means of human intervention performed within the cell fromwhich it originates. See, e.g., Compounds and Methods for Site DirectedMutagenesis in Eukaryotic Cells, Kmiec, U.S. Pat. No. 5,565,350; In VivoHomologous Sequence Targeting in Eukaryotic Cells; Zarling et al.,PCT/US93/03868. Likewise, a naturally occurring nucleic acid (e.g., apromoter) becomes isolated if it is introduced by non-naturallyoccurring means to a locus of the genome not native to that nucleicacid. Nucleic acids which are “isolated” as defined herein, are alsoreferred to as “heterologous” nucleic acids.

As used herein, “nucleic acid” includes reference to adeoxyribonucleotide or ribonucleotide polymer in either single- ordouble-stranded form, and unless otherwise limited, encompasses knownanalogues having the essential nature of natural nucleotides in thatthey hybridize to single-stranded nucleic acids in a manner similar tonaturally occurring nucleotides (e.g., peptide nucleic acids).

As used herein, the term “plant” includes reference to whole plants,plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cellsand progeny of same. Plant cell, as used herein includes, withoutlimitation, seeds, suspension cultures, embryos, meristematic regions,callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen,and microspores. The class of plants which can be used in the methods ofthe invention is generally as broad as the class of higher plantsamenable to transformation techniques, including both monocotyledonousand dicotyledonous plants.

As used herein, “polynucleotide” includes reference to adeoxyribopolynucleotide, ribopolynucleotide, or analogs thereof thathave the essential nature of a natural ribonucleotide in that theyhybridize, under stringent hybridization conditions, to substantiallythe same nucleotide sequence as naturally occurring nucleotides and/orallow translation into the same amino acid(s) as the naturally occurringnucleotide(s). A polynucleotide can be full-length or a subsequence of anative or heterologous structural or regulatory gene. Unless otherwiseindicated, the term includes reference to the specified sequence as wellas the complementary sequence thereof. Thus, DNAs or RNAs with backbonesmodified for stability or for other reasons are “polynucleotides” asthat term is intended herein. Moreover, DNAs or RNAs comprising unusualbases, such as inosine, or modified bases, such as tritylated bases, toname just two examples, are polynucleotides as the term is used herein.It will be appreciated that a great variety of modifications have beenmade to DNA and RNA that serve many useful purposes known to those ofskill in the art. The term polynucleotide as it is employed hereinembraces such chemically, enzymatically or metabolically modified formsof polynucleotides, as well as the chemical forms of DNA and RNAcharacteristic of viruses and cells, including among other things,simple and complex cells.

The terms “polypeptide” and “peptide” are used interchangeably herein torefer to a polymer of amino acid residues. A protein can contain one ormore polypeptides. The terms apply to amino acid polymers in which oneor more amino acid residue is an artificial chemical analogue of acorresponding naturally occurring amino acid, as well as to naturallyoccurring amino acid polymers. The essential nature of such analogues ofnaturally occurring amino acids is that, when incorporated into aprotein, that protein is specifically reactive to antibodies elicited tothe same protein but consisting entirely of naturally occurring aminoacids. The terms “polypeptide”, “peptide” and “protein” are alsoinclusive of modifications including, but not limited to, glycosylation,lipid attachment, sulfation, gamma-carboxylation of glutamic acidresidues, hydroxylation, deamidation, cross-linking, andADP-ribosylation. It will be appreciated, as is well known and as notedabove, that polypeptides are not always entirely linear. For instance,polypeptides can be branched as a result of ubiquitination, and they canbe circular, with or without branching, generally as a result of posttranslation events, including natural processing event and eventsbrought about by human manipulation which do not occur naturally.Circular, branched and branched circular polypeptides can be synthesizedby non-translation natural process and by entirely synthetic methods, aswell. Further, this invention contemplates the use of both themethionine-containing and the methionine-less amino terminal variants ofthe protein of the invention.

The term “residue” or “amino acid residue” or “amino acid” are usedinterchangeably herein to refer to an amino acid that is incorporatedinto a protein, polypeptide, or peptide (collectively “protein”). Theamino acid can be a naturally occurring amino acid and, unless otherwiselimited, can encompass non-natural analogs of natural amino acids thatcan function in a similar manner as naturally occurring amino acids.

“Terminal fusions of a glycinin polypeptide” refer to the N and Ctermini present before cleavage by VPE, as opposed to new termini formedat the VPE cleavage site.

As used herein, “transgenic plant” includes reference to a plant whichcomprises within its genome a non-native polynucleotide. Generally, thenon-native polynucleotide is stably integrated within the genome suchthat the polynucleotide is passed on to successive generations. Thenon-native polynucleotide can be integrated into the genome alone or aspart of a recombinant expression cassette. “Transgenic” is used hereinto include any cell, cell line, callus, tissue, plant part or plant, thegenotype of which has been altered by the presence of a non-nativenucleic acid including those transgenics initially so altered as well asthose created by sexual crosses or asexual propagation from the initialtransgenic. The term “transgenic” as used herein does not encompass thealteration of the genome (chromosomal or extra-chromosomal) byconventional plant breeding methods or by naturally occurring eventssuch as random cross-fertilization, non-recombinant viral infection,non-recombinant bacterial transformation, non-recombinant transposition,or spontaneous mutation.

The use of the term “DNA constructs” herein is not intended to limit thepresent invention to nucleotide constructs comprising DNA. Those ofordinary skill in the art will recognize that nucleotide constructs,particularly polynucleotides and oligonucleotides, comprised ofribonucleotides and combinations of ribonucleotides anddeoxyribonucleotides can also be employed in the methods disclosedherein. Thus, the DNA constructs of the present invention encompass allnucleotide constructs that can be employed in the methods of the presentinvention including, but not limited to, those comprised ofdeoxyribonucleotides, ribonucleotides, and combinations thereof. Suchdeoxyribonucleotides and ribonucleotides include both naturallyoccurring molecules and synthetic analogues. The nucleotide constructsof the invention also encompass all forms of nucleotide constructsincluding, but not limited to, single-stranded forms, double-strandedforms, hairpins, stem-and-loop structures, and the like.

The isolated nucleic acids of the present invention can be made using(a) standard recombinant methods, (b) synthetic techniques, orcombinations thereof. The nucleic acids can conveniently comprisesequences in addition to a polynucleotide of the present invention. Forexample, a multi-cloning site comprising one or more endonucleaserestriction sites can be inserted into the nucleic acid to aid inisolation of the polynucleotide. Also, translatable sequences can beinserted to aid in the isolation or detection of the translatedpolypeptide of the present invention. For example, a hexa-histidinemarker sequence provides a convenient means to purify the proteins ofthe present invention. A polynucleotide of the present invention can beattached to a vector, adapter, or linker for cloning and/or expressionof a polynucleotide of the present invention. Additional sequences canbe added to such cloning and/or expression sequences to optimize theirfunction in cloning and/or expression, to aid in isolation of thepolynucleotide, or to improve the introduction of the polynucleotideinto a cell.

Use of cloning vectors, expression vectors, adapters, and linkers iswell known and extensively described in the art. For a description ofvarious nucleic acids see, for example, Stratagene Cloning Systems,current catalog, (La Jolla, Calif.); Amersham Life Sciences, Inc,current catalog, (Arlington Heights, Ill.), and Novagen, Inc. currentcatalog, (Madison, Wis.).

The isolated nucleic acid compositions of this invention, such as RNA,cDNA, genomic DNA, or a hybrid thereof, can be obtained from plantbiological sources using any number of cloning methodologies known tothose of skill in the art. In some embodiments, oligonucleotide probeswhich selectively hybridize, under stringent conditions, to thepolynucleotides of the present invention are used to identify thedesired sequence in a cDNA or genomic DNA library. Isolation of RNA, andconstruction of cDNA and genomic libraries can be performed by methodswell known to those of ordinary skill in the art.

The sequences of the invention are provided in expression cassettes forexpression in the plant of interest. The cassette will include 5′ and 3′regulatory sequences operably linked to a soybean glycinin nucleic acidsequence.

The cassette can additionally contain at least one additional gene to becotransformed into the organism. Alternatively, the additional gene(s)can be provided on multiple expression cassettes.

The expression cassette will include in the 5′-3′ direction oftranscription, a transcriptional and translational initiation region, aDNA sequence of the invention, and a transcriptional and translationaltermination region functional in plants. The transcriptional initiationregion, the promoter, can be native or analogous or foreign orheterologous to the plant host. Additionally, the promoter can be thenatural sequence or alternatively a synthetic sequence. By “foreign” isintended that the transcriptional initiation region is not found in thenative plant into which the transcriptional initiation region isintroduced. As used herein, a chimeric gene comprises a coding sequenceoperably linked to a transcription initiation region that isheterologous to the coding sequence.

A number of promoters can be used in the practice of the invention. Thepromoters can be selected based on the desired timing, localization andlevel of expression genes encoding enzymes in a plant. Constitutive,seed-preferred, germination-preferred, tissue-preferred andchemical-regulatable promoters can be used in the practice of theinvention. Such constitutive promoters include, for example, the corepromoter of the Rsyn7 promoter and other constitutive promotersdisclosed in WO 99/43838 and U.S. Pat. No. 6,072,050; the core CaMV 35Spromoter (Odell et al. (1985) Nature 313:810-812); rice actin (McElroyet al. (1990) Plant Cell 2:163-171); ubiquitin (Christensen et al.(1989) Plant Mol. Biol. 12:619-632 and Christensen et al. (1992) PlantMol. Biol. 18:675-689); PEMU (Last et al. (1991) Theor. Appl. Genet.81:581-588); MAS (Velten et al. (1984) EMBO J. 3:2723-2730); ALSpromoter (U.S. Pat. No. 5,659,026), and the like. Other constitutivepromoters include, for example, U.S. Pat. Nos. 5,608,149; 5,608,144;5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; and 5,608,142.

The methods of the invention are useful for producing modified glycininsin seeds. Toward this end, the coding sequences for the proteins of theinvention can be utilized in expression cassettes or DNA constructs withseed-preferred promoters, seed-development promoters (those promotersactive during seed development), as well as seed-germination promoters(those promoters active during seed germination). For dicots, suchseed-preferred promoters include, but are not limited to, those from thefollowing genes: glycinin, phaseolin, napin, β-conglycinin, soybeanlectin, Kunitz trypsin inhibitor, and the like.

To achieve the desired subcellular location of a protein, sequenceencoding a signal peptide can be included in the expression cassette.For example, DNA sequence encoding the signal peptide of preproglycinincan be operably linked to the DNA sequence encoding the proglycininfusion of interest.

The termination region can be native with the transcriptional initiationregion, can be native with the operably linked DNA sequence of interest,or can be derived from another source. Convenient termination regionsare available from the Ti-plasmid of A. tumefaciens, such as theoctopine synthase and nopaline synthase termination regions. See alsoGuerineau et al. (1991) Mol. Gen. Genet. 262:141-144; Proudfoot (1991)Cell 64:671-674; Sanfacon et al. (1991) Genes Dev. 5:141-149; Mogen etal. (1990) Plant Cell 2:1261-1272; Munroe et al. (1990) Gene 91:151-158;Ballas et al. (1989) Nucleic Acids Res. 17:7891-7903; and Joshi et al.(1987) Nucleic Acid Res. 15:9627-9639.

Additional sequence modifications are known to enhance gene expressionin a cellular host. These include elimination of sequences encodingspurious polyadenylation signals, exon-intron splice site signals,transposon-like repeats, and other such well-characterized sequencesthat can be deleterious to gene expression. The G-C content of thesequence can be adjusted to levels average for a given cellular host, ascalculated by reference to known genes expressed in the host cell. Whenpossible, the sequence is modified to avoid predicted hairpin secondarymRNA structures.

The expression cassettes can additionally contain 5′ leader sequences inthe expression cassette construct. Such leader sequences can act toenhance translation. Translation leaders are known in the art andinclude: picornavirus leaders, for example, EMCV leader(Encephalomyocarditis 5′ noncoding region) (Elroy-Stein et al. (1989)Proc. Natl. Acad. Sci. USA 86:6126-6130); potyvirus leaders, forexample, TEV leader (Tobacco Etch Virus) (Gallie et al. (1995) Gene165(2):233-238), MDMV leader (Maize Dwarf Mosaic Virus) (Virology154:9-20), and human immunoglobulin heavy-chain binding protein (BiP)(Macejak et al. (1991) Nature 353:90-94); untranslated leader from thecoat protein mRNA of alfalfa mosaic virus (AMV RNA 4) (Jobling et al.(1987) Nature 325:622-625); tobacco mosaic virus leader (TMV) (Gallie etal. (1989) in Molecular Biology of RNA, ed. Cech (Liss, New York), pp.237-256); and maize chlorotic mottle virus leader (MCMV) (Lommel et al.(1991) Virology 81:382-385). See also, Della-Cioppa et al. (1987) PlantPhysiol. 84:965-968. Other methods known to enhance translation can alsobe utilized, for example, introns, and the like.

In preparing the expression cassette, the various DNA fragments can bemanipulated, so as to provide for the DNA sequences in the properorientation and, as appropriate, in the proper reading frame. Towardthis end, adapters or linkers can be employed to join the DNA fragmentsor other manipulations can be involved to provide for convenientrestriction sites, removal of superfluous DNA, removal of restrictionsites, or the like. For this purpose, in vitro mutagenesis, primerrepair, restriction, annealing, resubstitutions, e.g., transitions andtransversions, can be involved.

It is further recognized that the components of the expression cassettecan be modified to increase expression. For example, truncatedsequences, nucleotide substitutions or other modifications can beemployed. See, for example Perlak et al. (1991) Proc. Natl. Acad. Sci.USA 88:3324-3328; Murray et al. (1989) Nucleic Acid Res. 17:477-498; andWO 91/16432.

The method of transformation/transfection is not critical to the instantinvention; various methods of transformation or transfection arecurrently available. As newer methods are available to transform cropsor other host cells they can be directly applied. Accordingly, a widevariety of methods have been developed to insert a DNA sequence into thegenome of a host cell to obtain the transcription and/or translation ofthe sequence to effect phenotypic changes in the organism. Thus, anymethod which provides for effective transformation/transfection can beemployed.

Transformation protocols can vary depending on the type of plant orplant cell, i.e., monocot or dicot, targeted for transformation.Suitable methods of introducing nucleotide sequences into plant cellsand subsequent insertion into the plant genome include microinjection(Crossway et al. (1986) Biotechniques 4:320-334), electroporation (Riggset al. (1986) Proc. Natl. Acad. Sci. USA 83:5602-5606,Agrobacterium-mediated transformation (Townsend et al., U.S. Pat. No.5,563,055; Zhao et al., U.S. Pat. No. 5,981,840), direct gene transfer(Paszkowski et al. (1984) EMBO J. 3:2717-2722), and ballistic particleacceleration (see, for example, Sanford et al., U.S. Pat. No. 4,945,050;Tomes et al., U.S. Pat. No. 5,879,918; Tomes et al., U.S. Pat. No.5,886,244; Bidney et al., U.S. Pat. No. 5,932,782; Tomes et al. (1995)“Direct DNA Transfer into Intact Plant Cells via MicroprojectileBombardment,” in Plant Cell, Tissue, and Organ Culture: FundamentalMethods, ed. Gamborg and Phillips (Springer-Verlag, Berlin); and McCabeet al. (1988) Biotechnology 6:923-926). Also see Weissinger et al.(1988) Ann. Rev. Genet. 22:421-477; Sanford et al. (1987) ParticulateScience and Technology 5:27-37 (onion); Christou et al. (1988) PlantPhysiol. 87:671-674 (soybean); McCabe et al. (1988) Bio/Technology6:923-926 (soybean); Finer and McMullen (1991) In Vitro Cell Dev. Biol.27P:175-182 (soybean); Singh et al. (1998) Theor. Appl. Genet.96:319-324 (soybean); Datta et al. (1990) Biotechnology 8:736-740(rice); Klein et al. (1988) Proc. Natl. Acad. Sci. USA 85:4305-4309(maize); Klein et al. (1988) Biotechnology 6:559-563 (maize); Tomes,U.S. Pat. No. 5,240,855; Buising et al., U.S. Pat. Nos. 5,322,783 and5,324,646; Tomes et al. (1995) “Direct DNA Transfer into Intact PlantCells via Microprojectile Bombardment,” in Plant Cell, Tissue, and OrganCulture: Fundamental Methods, ed. Gamborg (Springer-Verlag, Berlin)(maize); Klein et al. (1988) Plant Physiol. 91:440-444 (maize); Fromm etal. (1990) Biotechnology 8:833-839 (maize); Hooykaas-Van Slogteren etal. (1984) Nature (London) 311:763-764; Bowen et al., U.S. Pat. No.5,736,369 (cereals); Bytebier et al. (1987) Proc. Natl. Acad. Sci. USA84:5345-5349 (Liliaceae); De Wet et al. (1985) in The ExperimentalManipulation of Ovule Tissues, ed. Chapman et al. (Longman, N.Y.),pp.197-209 (pollen); Kaeppler et al. (1990) Plant Cell Reports 9:415-418and Kaeppler et al. (1992) Theor. Appl. Genet 84:560-566(whisker-mediated transformation); D'Halluin et al. (1992) Plant Cell4:1495-1505 (electroporation); Li et al. (1993) Plant Cell Reports12:250-255 and Christou and Ford (1995) Annals of Botany 75:407-413(rice); Osjoda et al. (1996) Nature Biotechnology 14:745-750 (maize viaAgrobacterium tumefaciens); all of which are herein incorporated byreference.

The cells that have been transformed can be grown into plants inaccordance with conventional ways. See, for example, McCormick et al.(1986) Plant Cell Reports 5:81-84. These plants can then be grown, andeither pollinated with the same transformed strain or different strains,and the resulting hybrid having constitutive expression of the desiredphenotypic characteristic identified. Two or more generations can begrown to ensure that expression of the desired phenotypic characteristicis stably maintained and inherited and then seeds harvested to ensureexpression of the desired phenotypic characteristic has been achieved.

Using the nucleic acids of the present invention, one can express aprotein of the present invention in a recombinantly engineered cell suchas bacteria, yeast, insect, mammalian, or preferably plant cells. Thecells produce the protein in a non-natural condition (e.g., in quantity,composition, location, and/or time), because they have been geneticallyaltered through human intervention to do so.

Additionally, nucleotide sequences of the invention can be used inmethods for producing modified glycinin in host organisms other thanplants, including but not limited to bacteria, yeasts and other fungi.Useful host organisms for modified glycinin production includeActinomycetes (e.g., Streptomyces sp. and Nocardia sp.); bacteria (e.g.,Alcaligenes (e.g., A. eutrophus), Bacillus cereus, B. subtilis, B.licheniformis, B. megaterium, Escherichia coli, Klebsiella (e.g., K.aerogenes and K. oxytoca), Lactobacillus, Methylomonas, Pseudomonas(e.g., P. putida and P. fluorescens); fungi (e.g., Aspergillus,Cephalosporium, and Penicillium); and yeast (e.g., Saccharomyces,Rhodotorula, Candida, Hansenula, and Pichia).

It is expected that those of skill in the art are knowledgeable in thenumerous expression systems available for expression of a nucleic acidencoding a protein of the present invention.

In brief summary, the expression of isolated nucleic acids encoding aprotein of the present invention will typically be achieved by operablylinking, for example, the DNA or cDNA to a promoter (which is eitherconstitutive or regulatable), followed by incorporation into anexpression vector. The vectors can be suitable for replication andintegration in either prokaryotes or eukaryotes. Typical expressionvectors contain transcription and translation terminators, initiationsequences, and promoters useful for regulation of the expression of theDNA encoding a protein of the present invention. To obtain high levelexpression of a cloned gene, it is desirable to construct expressionvectors which contain, at the minimum, a promoter to directtranscription, a ribosome binding site for translational initiation, anda transcription/translation terminator. One of skill will recognize thatmodifications can be made to a protein of the present invention withoutdiminishing its biological activity. Some modifications can be made tofacilitate the cloning, expression, or incorporation of the targetingmolecule into a fusion protein. Such modifications are well known tothose of skill in the art and include, for example, a methionine addedat the amino terminus to provide an initiation site, or additional aminoacids (e.g., poly His) placed on either terminus to create convenientlylocated purification sequences. Restriction sites or termination codonscan also be introduced.

Prokaryotic cells can be used as hosts for expression. Prokaryotes mostfrequently are represented by various strains of E. coi; however, othermicrobial strains can also be used. Commonly used prokaryotic controlsequences which are defined herein to include promoters fortranscription initiation, optionally with an operator, along withribosome binding site sequences, include such commonly used promoters asthe beta lactamase (penicillinase) and lactose (lac) promoter systems(Chang et al., Nature 198:1056 (1977)), the tryptophan (trp) promotersystem (Goeddel et al., Nucleic Acids Res. 8:4057 (1980)) and the lambdaderived P L promoter and N-gene ribosome binding site (Shimatake et al.,Nature 292:128 (1981)). The inclusion of selection markers in DNAvectors transfected in E. coli is also useful. Examples of such markersinclude genes specifying resistance to ampicillin, tetracycline, orchloramphenicol.

The vector is selected to allow introduction into the appropriate hostcell. Bacterial vectors are typically of plasmid or phage origin.Appropriate bacterial cells are infected with phage vector particles ortransfected with naked phage vector DNA. If a plasmid vector is used,the bacterial cells are transfected with the plasmid vector DNA.Expression systems for expressing a protein of the present invention areavailable using Bacillus sp. and Salmonella (Palva et al., Gene22:229-235 (1983); Mosbach et al., Nature 302:543-545 (1983)).

The proteins of this invention, recombinant or synthetic, can bepurified to substantial purity by standard techniques well known in theart, including detergent solubilization, selective precipitation withsuch substances as ammonium sulfate, column chromatography,immunopurification methods, and others. See, for instance, R. Scopes,Protein Purification: Principles and Practice, Springer-Verlag: New York(1982); Deutscher, Guide to Protein Purification, Academic Press (1990).For example, antibodies can be raised to the proteins as describedherein. Purification from E. coli can be achieved following proceduresdescribed in U.S. Pat. No. 4,511,503. The protein can then be isolatedfrom cells expressing the protein and further purified by standardprotein chemistry techniques as described herein.

Detection of the expressed protein in all in vivo systems is achieved bymethods known in the art and include, for example, radioimmunoassays,Western blotting techniques or immunoprecipitation.

The following examples are offered by way of illustration and not by wayof limitation.

EXAMPLES

Description and Isoelectric Points of Glycinin Fusions

Examples of fusions to proglycinin1 (encoded by the Gy1 gene) forexpression in E. coli are listed in the accompanying table. Similarfusions can be made with other proglycinins or with proglycinin homologs(such as those listed in FIG. 2of Adachi et al, Proc. Natl. Acad. Sci.USA 10:100, 7395-7400 (2003). The isoelectric points (pI) werecalculated by using Vector NTI software (InforMax, Inc., Gaithersburg,Md.). Further descriptions of some of the fusions follow the table. Whenthe fusions are expressed in E. coli, the start methionine is often notretained (pET System Manual, Novagen, Inc., Madison, Wis.). TABLE 1Proglycinin Fusions. The residues are fused to the core sequence ofproglycinin1. The core sequence is SREQP . . . [464 amino acids] . . .KRAVA. The sequence of the 464 amino acids is identical to thecorresponding “G1” sequence of Nielsen et al, Plant Cell 1: 313-328(1989), except that the sequence used here has L, rather than I, atposition 278 of the published sequence. Property of Calculatedunderlined pl of entire Expressed Name N-terminal Fusion C-terminalFusion residues. fusion. in E. coli. WT (wild type MG — — 5.8 yesproglycinin1 used for E. coli expression) KRGly MAKRKRKRGS Basic 6.8 yesGlyKR MG GGGSKRKRKR Basic 6.8 yes KRGlyKR MAKRKRKRGS GGGSKRKRKR Basic8.6 yes DEGly MADEDEDEGS Acidic 5.3 yes GlyDE MG GGGSDEDEDE Acidic 5.3yes DEGlyDE MADEDEDEGS GGGSDEDEDE Acidic 5.0 yes KEGly MAKEKEKEGS 3basic/3 acidic 5.8 yes GlyKE MG GGGSKEKEKE 3 basic/3 acidic 5.8 noKEGlyKE MAKEKEKEGS GGGSKEKEKE 3 basic/3 acidic 5.8 no SQGly MASQSQSQGSHydrophilic but 5.8 yes uncharged GlySQ MG GGGSSQSQSQ Hydrophilic but5.8 yes uncharged SQGlySQ MASQSQSQGS GGGSSQSQSQ Hydrophilic but 5.8 yesuncharged AGly MAAAAAAGS Weakly 5.8 yes hydrophobic GlyA MG GGGSAAAAAAWeakly 5.8 no hydrophobic AGlyA MAAAAAAGS GGGSAAAAAA Weakly 5.8 nohydrophobic IGly MAIIIIIIGS Strongly 5.8 yes hydrophobic GlyI MGGGGSIIIIII Strongly 5.8 no hydrophobic IGlyI MAIIIIIIGS GGGSIIIIIIStrongly 5.8 no hydrophobic ThioGly Soybean Acidic 5.4 yes thioredoxin.GlyThio MG Soybean Acidic 5.4 no thioredoxin. LEAGly Late Basic 6.3 noembryogenesis abundant protein. GlyLEA Late Basic 6.3 no embryogenesisabundant protein. GlyBHL8 MG BHL8 Basic 8.2 yes GlyBHL9 MG BHL9 Basic6.5 no Gly—Gly Proglycinin1 fusion with itself. — 5.8 yes Gly-aCGProglycinin1 fusion with mature α — 5.1 no subunit of β-ConglycininDEGlyKR MADEDEDEGS GGGSKRKRKR Acidic N terminal; 5.8 yes basic Cterminal. KRGlyDE MAKRKRKRGS GGGSDEDEDE Basic N terminal; 5.8 no acidicC terminal. GlyKR(4 basic) MG GGGSKRKR Basic 6.3 yes GlyKR(2 basic) MGGGGSKR Basic 6.0 yes GlyKR(no linker) MG KRKRKR Basic 6.8 no ThioGlyDESoybean GGGSDEDEDE Acidic 5.2 yes thioredoxin. acgeGlyDEExtension region GGGSDEDEDE Acidic 4.7 no of mature α subunit ofβ-Conglycinin GlyF6 MG GGGSFFFFFF Aromatic 5.8 no GlyF4 MG GGGSFFFFAromatic 5.8 no GlyF2 MG GGGSFF Aromatic 5.8 no

BHL8 (Barley High Lysine Protein 8) and BHL9 (Barley High Lysine Protein9) are derivatives of barley chymotrypsin inhibitor-2 (CI-2) that werepreviously engineered for a high essential amino acid content to improvethe nutritional value of maize and other crops (Roesler and Rao; 2000,Protein Sci. 9:1642-1650); (Roesler and Rao; 2001, J. Agric. Food Chem.49:3443-3451). The 4 ^(th) residue of the BHL8 used in the present workdiffers from the BHL8 reported in Roesler and Rao (2000). The amino acidat this position was isoleucine in the present study, methionine in thepublished BHL8, and leucine in wild type CI-2, and there are a widevariety of other residues at this position in CI-2 homologs. Theposition of this substitution is position 20 according to the numberingof the above Roesler and Rao (2000) reference. The soybean thioredoxinused here was inactivated by mutating an active site cysteine atposition 41 to serine. The LEA protein used here is also known as seedmaturation protein PM30 (Chow et al.; Plant Physiol. 121:1054 (1999);Accession number AF117884). It includes 6 repeats of 11 amino acids inits sequence. For the LEAGly fusion, two asn residues near theC-terminus of LEA were mutated to gin—the 2nd to the last and the 5th tothe last residues. For the GlyLEA fusion, no substitutions in the LEAprotein were used. Short linkers (SEQ ID NO: 19) were included for thefusions with BHL8, and LEA.

Expression of Fusions in E. coli and Purification

The recombinant protein expression system used for E. coli is the pETSystem (Novagen). The DNA sequences encoding any desired glycininfusions could be obtained by ordering them from a commercial vendor suchas The Midland Certified Reagent Company (Midland, Tex.). However, mostof the fusions described here were made as follows. Polymerase chainreaction with the wild type DNA was performed to add a BamH1 restrictionsite (encoding glycine-serine) at the 5′ end to facilitate N-terminalfusions, or alternatively, to add sequence at the 3′ end encoding twoglycines followed by a BamH1 site encoding glycine-serine, to facilitateC-terminal fusions. The short peptide N terminal fusions of Table 1 wereprepared by annealing pairs of synthetic oligonucleotides that encodedthe desired peptide and gave overhangs suitable for ligating into theNco I site that encodes the start methionine, and the BamH1 site. Theshort peptide C terminal fusions of Table 1 were prepared by annealingpairs of synthetic oligonucleotides that encoded the desired peptide andgave overhangs suitable for ligating into the BamH1 site and a Hind IIIsite in the pET expression vector downstream from the stop codon. Tomake fusions at both terminii, a fragment containing the N-terminalfusion was ligated to a fragment containing the C-terminal fusion at anNde I site in the glycinin gene. Annealed oligonucleotides were not usedfor the larger protein fusions such as thioredoxin, BHL8, or the LEAprotein. Rather, polymerase chain reaction was performed to createappropriate terminii for ligation.

Using the names of Table 1, the proglycinin fusion proteins KRGly,GlyKR, KRGlyKR, DEGly, GlyDE, DEGlyDE, SQGly, GlySQ, SQGlySQ, KEGly,AGly, IGly, GlyBHL8, ThioGly, Gly-Gly, DEGlyKR, GlyKR(4 basic), GlyKR(2basic) and wild type were expressed in E. coli as the proglycinin formusing the pET 28 expression vector (Novagen) and most were purified by acombination of ion exchange chromatography and isoelectricprecipitation. Some flexibility in expression methods was observed, withboth 37° C. and 30° C. incubation temperatures being used successfully,both 2X YT and LB media being used successfully, and with BL21 (DE3),BL21-Codon Plus (DE3)-RP, and BL21-Codon Plus (DE3)-RIL (Stratagene) E.coli strains being used successfully. The procedure for GlyKR isdescribed in detail as a typical example, and then Table 2 willsummarize differences among the fusion protein preps with respect tolysis buffers and purification conditions.

The GlyKR protein was expressed at 37° C. in 2X YT media with E. colistrain BL21 -CodonPlus(DE3)-RP (Stratagene). Total volume was 800 ml ina 2.8 liter baffled shake flask. Induction was at OD600=0.8 with 1 mMIPTG and cells were harvested 3 to 4 hours later and frozen. The cellswere thawed and lysed in 40 ml of 50 mM Hepes (pH 8.0), 2 mM EDTA, 300mM NaCl, 0.1% Triton X-100, 0.1 mg/ml lysozyme for 30 min at 25° C.Alternatively, the NaCl concentration was changed midway through thelysis period (150 mM NaCl was used initially, then increased to 300 mMNaCl for the remainder of the lysis period). DNA was sheared bysonication. Centrifugation was done at 17,000 g 15 min. The supernatantwas poured through one layer of Miracloth and then purified by SPSepharose cation exchange chromatography. The protein was applied to anSP Sepharose column equilibrated with 10 mM sodium phosphate, 300 mMNaCl, pH 7.0, and washed with the same buffer. Elution was with 10 mMsodium phosphate, 500 mM NaCl, pH 7.0. The eluted protein was thenprecipitated by dialysis overnight in 5 mM Tris, pH 8.0. Theprecipitated protein was centrifuged 17,000 g 10 min, the pellet waswashed with dialysis buffer, and the pelleted protein was resuspended in10 mM sodium acetate, 500 mM NaCl, pH 5.0. The still insoluble materialwas removed by centrifugation. If needed, a final purification bySuperose 6 gel permeation chromatography in the same buffer was done.The purified fusion protein was concentrated by Centricon-30ultrafiltration and stored either at 4° C. or by freezing in liquidnitrogen without glycerol. The protein concentration was determined byamino acid analysis, and the absorbance at 280 nm of the same proteinsolution was taken to determine the extinction coefficient for futureuse. Alternatively, the protein was quantitated by the method ofBradford, using the Coomassie Plus® reagent from Pierce, with BovineSerum Albumen as standard. A summary of purification conditionsappropriate for the fusions that have already been expressed andpurified is presented in Table 2. TABLE 2 Lysis buffers and purificationmethods Lysis buffer Buffers for gel (in addition to 2 mM Material andbuffer for Buffers for permeation EDTA, 0.1% Triton X-100, ion exchangechromatography. isoelectric chromatography Protein and 0.1 mg/mllysozyme) (Sepharose is abbreviated Seph) precipitation (if needed)KRGly 50 mM Hepes, SP Seph; 10 mM 5 mM Tris, 10 mM sodium acetate, 300mM NaCl, sodium phosphate, pH 7, pH 8 500 mM NaCl, pH 5 pH 8. 300-600 mMNaCl GlyKR 50 mM Hepes, SP Seph; 10 mM 5 mM Tris, 10 mM sodium acetate,300 mM NaCl, sodium phosphate, pH 7, pH 8 500 mM NaCl, pH 5 pH 8.300-500 mM NaCl KRGlyKR 50 mM Hepes, SP Seph; 10 mM 5 mM Tris, 10 mMsodium acetate, 300 mM NaCl, sodium phosphate, pH 7, pH 8 500 mM NaCl,pH 5 pH 8. 600-1000 mM NaCl DEGly 50 mM Tris, Q Seph; 20 mM 2 mM Mes, 10mM Tris, 200 mM NaCl, Tris, pH 8, pH 5.5 500 mM NaCl, pH 8 pH 8 200-350mM NaCl GlyDE 50 mM Tris, Q Seph; 20 mM 2 mM Mes, 10 mM Tris, 250 mMNaCl, Tris, pH 8, pH 5.5 500 mM NaCl, pH 8 pH 8 250-350 NaCl DEGlyDE 50mM Tris, Q Seph; 20 mM 2 mM sodium 10 mM Tris, 150 mM NaCl, Tris, pH 8,acetate, pH 5 500 mM NaCl, pH 8 pH 8 250-350 mM NaCl KEGly 50 mM Tris, QSeph; 20 mM 2 mM Mes, 10 mM Tris, 150 mM NaCl, Tris pH 8, pH 6.0 500 mMNaCl, pH 8 pH 8 150-250 mM NaCl SQGly 50 mM Tris, Q Seph; 20 mM 2 mMMes, 10 mM Tris, 150 mM NaCl, Tris pH 8, pH 6.0 500 mM NaCl, pH 8 pH 8150-250 mM NaCl GlySQ 50 mM Tris, Q Seph; 20 mM 2 mM Mes, 10 mM Tris,150 mM NaCl, Tris pH 8, pH 6.0 500 mM NaCl, pH 8 pH 8 150-250 mM NaClSQGlySQ 50 mM Tris, Q Seph; 20 mM 2 mM Mes, 10 mM Tris, 150 mM NaCl,Tris pH 8, pH 6.0 500 mM NaCl, pH 8 pH 8 150-250 mM NaCl DEGlyKR 50 mMHepes, SP Seph; 10 mM Not done, but 10 mM sodium acetate, 300 mM NaCl,sodium phosphate, pH 7, 5 mM Tris, pH 8.0 500 mM NaCl, pH 5 pH 8 400-500mM NaCl. should work. GlyKR(4 50 mM Hepes, SP Seph; 10 mM 2 mM Mes, 10mM sodium acetate, basic) 300 mM NaCl, sodium phosphate, pH 7, pH 6.0.500 mM NaCl, pH 5 pH 8 300-500 mM NaCl. GlyKR(2 50 mM Hepes, SP Seph; 10mM 2 mM Mes, 10 mM sodium acetate, basic) 100 mM NaCl, sodium phosphate,pH 7, pH 6.0. 500 mM NaCl, pH 5 pH 8 100-300 mM NaCl. ThioGly 50 mMTris, Q Seph; 20 mM 2 mM Mes, 10 mM Tris, 150 mM NaCl, Tris pH 8, pH 5.5500 mM NaCl, pH 8 pH 8 150-250 mM NaCl GlyBHL8 50 mM Hepes, SP Seph; 10mM 5 mM Tris, 10 mM sodium acetate, 200 mM NaCl, sodium phosphate, pH 7,pH 8 500 mM NaCl, pH 5 pH 8 200-400 mM NaCl. Wild type 50 mM Tris, QSeph; 20 mM 2 mM Mes, 10 mM Tris, proglycinin 1 150 mM NaCl, Tris pH 8,pH 6.0 500 mM NaCl, pH 8 pH 8 150-250 mM NaClSolubility

Using the names of Table 1, the proglycinin fusion proteins KRGly,GlyKR, KRGlyKR, DEGly, GlyDE, DEGlyDE, SQGly, GlySQ, SQGlySQ, KEGly,DEGlyKR, GlyKR(4 basic), GlyKR(2 basic), Gly-BHL8, Thio-Gly, and wildtype were expressed in E. coli as the proglycinin (trimeric,unprocessed) form, purified, and characterized with respect tosolubility. The purified proteins were incubated in 20 mM buffer, 20 mMNaCl for 16 hours at 25° C. at a concentration of 0.5 mg/ml protein.Following centrifugation at 17,000 g for 10 min., the supernatant wasassayed for soluble protein using the method of Bradford with theCoomassie Plus reagent (Pierce) and bovine serum albumen as standard.The buffers used were Caps for pH 11.5, 11, 10.5, 10.0, and 9.5; Trisfor pH 9.0 and 8.5; Hepes for pH 8, 7.5, and 7; Mes for pH 6.5, 6, and5.5; and sodium acetate for pH 5, 4.5, 4, and 3.5. The basic fusionsKRGly, GlyKR, KRGlyKR, GlyKR(4 basic), and GlyBHL8 had significantlygreater solubility than wild type proglycinin1 at pH 3.5 to pH 5.5. Forexample, at pH 5.5, the wild type proglycinin was 19% soluble, whileKRGlyKR was 93% soluble. These basic fusions also had less solubilitythan wild type from pH 6.5 to pH 10.0. Thus, fusion of basic residues toproglycinin1 had a major impact on solubility. The GlyKR(2 basic)protein also had increases in solubility at pH 3.5 to pH 5.5, anddecreases in solubility at pH 6.5 to 10.0, but the changes were smallerthan those observed for the other basic fusions. The acidic fusionsDEGly, GlyDE, DEGlyDE, and ThioGly had solubility minima at pH 5.0 or5.5, clearly different than the wild type solubility minimum at pH 6.0.This shift in the solubility curve resulted in greater than wild typesolubility for the acidic fusions at pH 6.0, 6.5, and 7.0. Thus, fusionof acidic residues to proglycinin1 had a significant effect onsolubility. The net neutral fusion KEGly (3 basic and 3 acidic residuesin the fused peptide), and the neutral fusions SQGly, GlySQ, and SQGlySQall had solubility minima at pH 6.0 like wild type, yet some had greaterthan wild type solubility from pH 4.0 to pH 5.0. The observation thatfusing as few as 6 basic or 6 acidic residues to either terminus ofproglycinin1 can result in such major changes in solubility behavior wasunexpected.

Gel Firmness

Gel firmness was determined for the purified KRGly, GlyKR, KRGlyKR,DEGly, GlyDE, SQGly, SQGlySQ, GlyBHL8, ThioGly, and wild type proteinsfollowing their expression in E. coli as the proglycinin (trimeric,unprocessed) form. Gels were formed as follows: The proteins wereconcentrated by ultrafiltration to 60 mg/ml in 20 mM potassiumphosphate, 500 mM NaCl, pH 7.50 μl of 60 mg/ml protein was transferredto a thin-walled 0.2 ml PCR tube. Samples were sonicated one minute toremove bubbles with a Branson ultrasonic cleaner B-220 (Shelton, Conn.,USA). The samples were heated and cooled in a PTC-100 ProgrammableThermal Controller from MJ Research, Inc., using the followingtemperature changes: 50° C. for 2 min; change from 50° to 98° C. at0.1°/sec; hold at 98° C. 5 min; change from 98° to 50° C. at 0.1°/sec;hold at 50° C. 2 min. Gel firmness was measured with a TA.XT.PlusTexture Analyzer (Texture Technologies Corp., Scarsdale, N.Y.) using a 2mm diameter cylindrical probe. The probe was pushed against the gels fora distance of 2 mm, using pre-test and test speeds of 0.5 mm/sec, apost-test speed of 10 mm/sec, and a trigger force of 1.5 grams. Thevalue (force in grams) at 1 mm distance was compared between gels. Thegels made from the basic peptide fusions KRGly, GlyKR, and KRGlyKR wereless firm than gels made from wild type proglycinin1. In contrast, gelsmade from the other fusions were more firm than gels made from wildtype. For example, values at 1 mm for wildtype, KRGlyKR, and SQGlySQgels were 20.1, 12.7, and 45.7 grams of force. Thus, fusion of even afew residues to proglycinin markedly changed gelation properties.

Differential Scanning Calorimetry

Differential scanning calorimetry was done to determine the thermaldenaturation temperatures for the purified KRGly, GlyKR, KRGlyKR, DEGly,GlyDE, DEGlyDE, SQGly, GlySQ, SQGlySQ, GlyBHL8, ThioGly, and wild typeproteins following their expression in E. coli as the proglycinin(trimeric, unprocessed) form. Scans were done from 30° C. to 110° C. ata rate of 90° C./hour, using a VP-DSC Microcalorimeter from MicroCal(Northampton, Mass.). Peak values at the thermal transition werecompared. The GlyBHL8 protein had a denaturation temperature of 78.3°C., which was 7.1° C. less than the wild type value of 85.4° C. For theThioGly protein, two transitions were observed, at 15.5 and 8.6° C. lessthan the wild type value. The two transitions may be due to independentunfolding of thioredoxin and proglycinin. Denaturation temperatures forthe other proteins were all within 3.4° C. of the wild type value.Because denaturation is a prerequisite for gelation, some proglycininfusions such as GlyBHL8 or ThioGly may form gels at a lower temperaturethan required for wild type protein gels.

Characterization of Oligomeric State

Gel permeation chromatography: Using the names of Table 1, theproglycinin fusion proteins GlyBHL8, ThioGly, KRGly, GlyKR, KRGlyKR,DEGly, GlyDE, DEGlyDE, SQGly, GlySQ, SQGlySQ, and wild type wereexpressed in E. coli as the unprocessed (trimeric, proglycinin) form,purified, and characterized with respect to oligomeric state. Superose 6gel permeation chromatography with appropriate molecular mass markerswas done with the purified proteins, using 10 mM Tris, 500 mM NaCl, pH8. The wild type protein eluted at a similar position as the aldolasemarker (158,000 mW), consistent with expectations for trimericproglycinin. All of the fusions eluted at a similar or slightly earlierposition than wild type, demonstrating that the fusions also assembledinto oligomers.

Proteolytic Stability of Glycinin Fusions

Using the names of Table 1, the proglycinin fusion proteins KRGly,GlyKR, KRGlyKR, DEGly, GlyDE, DEGlyDE, GlyBHL8, ThioGly, and wild typewere expressed in E. coli as the proglycinin (trimeric, unprocessed)form, purified, and characterized with respect to stability againstdigestion by the protease chymotrypsin. The purified proteins wereincubated with chymotrypsin at 37° C. for 1, 2, 4, 8, 15, 30 or 60 min.Incubation was done in 100 mM Tris (pH 8.0), 500 mM NaCl, 1 mM CaCl₂,with a ratio (wt:wt) of 1:20 chymotrypsin:substrate protein. Resultswere assessed by SDS-PAGE. The stability against digestion bychymotrypsin was similar for wild type and for all of the glycininfusions except for ThioGly. The similar proteolytic stability suggestedthat the fusion proteins were correctly folded, because malfoldedproteins would have been more susceptible to the protease. The resultsof the ThioGly fusion suggest that all or part of the thioredoxin wasclipped off by the protease. Incubations with 1:100 trypsin:substratewere also done for GlyBHL8, ThioGly and wild type, and the rate ofdigestion with this protease was approximately the same for wild typeand the two fusion proteins, suggesting that the fusion proteins werecorrectly folded.

In Planta Expression of Glycinin Fusions and Incorporation into Hexamers

Constructs appropriate for expression in plants were prepared that fusedthe glycinin1 promoter and signal peptide (both encoded by the Gy1 gene)to the ThioGly protein, the GlyBHL8 protein, the KRGlyKR protein, andthe DEGlyDE protein (SEQ ID NOS: 35, 36, 37, 38, 39, 40, 41, 42),followed by the phaseolin 3′ non-translated region. Three amino acids ofmature glycinin1 (Phe-Ser-Ser) were also included following the signalpeptide in the ThioGly, KRGlyKR, and DEGlyDE constructs.

Soybean embryogenic suspension cultures were transformed with theplasmids and DNA fragments by the method of particle gun bombardment(Klein et al., 1987, Nature 327:70). A DuPont Biolistic PDS1000/HEinstrument (helium retrofit) was used for all transformations. Proteinexpression was assessed by western blots. Antibodies against BHL8 wereused to detect the GlyBHL8 fusion. The GlyBHL8 protein was highlyexpressed and stably accumulated in both soybean somatic embryos andmature seeds. Antibodies against wild type proglycinin 1 plus a mobilitydifference from wild type during SDS-PAGE were used to detect theThioGly fusion. The ThioGly fusion expressed well in soybean embryos,thus demonstrating that glycinin fusion proteins with either an N or a Cterminal fusion could accumulate in plants. Furthermore, the mobility inSDS-PAGE suggested that the fusion proteins were processed by VPE. Toassess whether the fusion proteins were incorporated into hexamers,protein fractionation followed by additional western blots was done.Proteins from untransformed or transformed soybean seeds were extractedand fractionated by 6%-22% sucrose density gradients (Gruis et al, PlantCell 16:270-290 (2004)), and fractions were then assessed by westernblots probed with the appropriate antibodies.

The GlyBHL8, and ThioGly were primarily in 11S hexamer fraction based onCoomassie Blue staining and Western blot, confirming that the fusionpolypeptides were incorporated into hexamers. Protein solubilityanalyses indicated that the 11S fraction of the GlyBHL8 soybean seedsprovided better solubility than the 11S fraction of the wild typesoybean seeds from pH 2.8-6.0. In summary, these results demonstratedthat glycinin fusions in plants can accumulate and can be incorporatedinto hexamers. The glycinin fusions can change the functionality of thesoybean seed proteins.

1. An isolated terminal fusion polypeptide comprising: a first soybeanglycinin or proglycinin polypeptide operably linked to at least a secondpolypeptide wherein the resulting terminal fusion polypeptide exhibitsmodified functional properties.
 2. A transformed soybean plantcomprising the terminal fusion polypeptide of claim
 1. 3. A soybeanprotein product comprising the terminal fusion polypeptide of claim 1.4. The fusion polypeptide of claim 1 wherein the second polypeptide isacidic.
 5. The fusion polypeptide of claim 4 wherein the calculated pIof the fusion polypeptide is from 0.4 to 1.1 pH units less than the pIof the wild type proglycinin or glycinin polypeptide.
 6. The fusionpolypeptide of claim 1 wherein the second polypeptide is basic.
 7. Thefusion polypeptide of claim 6 wherein the calculated pI of the fusionpolypeptide is from 0.2 to 2.8 pH units greater than the pI of the wildtype proglycinin or glycinin polypeptide.
 8. The second polypeptide ofclaim 1 comprising a polypeptide selected from the group consisting of:SEQ ID NOS: 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and
 18. 9.The second polypeptide of claim 1 comprising a polypeptide selected fromthe group consisting of: soybean thioredoxin, LEA, BHL-8, BHL-9, soybeanglycinin 1, and alpha-conglycinin.
 10. An expression cassette comprisinga promoter operably linked to a first soybean glycinin or proglycininpolynucleotide operably linked at either terminus to at least a secondpolynucleotide wherein the resulting fusion polypeptide exhibitsmodified functional properties.
 11. The expression cassette of claim 10wherein the first and at least second polynucleotide are operably linkedto a third polynucleotide at the opposite terminus; wherein theresulting fusion polypeptide exhibits modified functional properties.12. The expression cassette of claim 10 wherein the at least secondpolynucleotide encodes a polypeptide selected from the group consistingof: SEQ ID NOS: 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18.13. The host cell of claim 12 that is a plant cell.
 14. A transgenicplant comprising at least one expression cassette of claim
 10. 15. Atransgenic seed from the plant of claim
 14. 16. A soybean proteinproduct derived from the processing of soybean seeds expressing asoybean glycinin or proglycinin protein with modified functionalproperties, the method comprising: a) introducing into a non-human hostcell an expression cassette comprising a promoter operably linked to afirst soybean glycinin or proglycinin polynucleotide operably linked ateither terminus to at least a second polynucleotide; wherein theresulting fusion polypeptide exhibits modified functional properties; b)growing the plant cell under plant-forming conditions to express theprotein with modified properties in the seed; and c) processing the seedto obtain a soybean protein product with modified properties.
 17. Thesoybean protein product of claim 16 wherein the fusion polypeptide isfurther operably linked to a polypeptide at the opposite terminus,wherein the resulting fusion polypeptide exhibits modified functionalproperties.
 18. The soybean protein product of claim 16 wherein themodified property is a change in solubility of the protein as comparedto wild-type.
 19. The soybean protein product of claim 16 wherein themodified property is a change in gel-forming ability of the protein ascompared to wild-type.
 20. The soybean protein product of claim 16wherein the modified property is a change in emulsifying ability of theprotein as compared to wild-type.